Literature DB >> 22543036

Adverse events associated with fluoroscopically guided sacroiliac joint injections.

Christopher T Plastaras1, Anand B Joshi, Cynthia Garvan, Gary P Chimes, Wesley Smeal, Joshua Rittenberg, Paul Lento, Steven Stanos, Colleen Fitzgerald.   

Abstract

OBJECTIVE: To describe the type, incidence, and factors that contribute to adverse events associated with fluoroscopically guided intra-articular sacroiliac joint injections (IASIJ).
DESIGN: A retrospective cohort study.
SETTING: Tertiary, academic, outpatient physical medicine and rehabilitation interventional spine clinic. PARTICIPANTS: English-speaking adults aged 18-90 years who underwent fluoroscopically guided IASIJ injections between March 8, 2004, and April 19, 2007.
INTERVENTIONS: After IASIJ injections, 3 senior researchers recorded the presence and types of adverse events. The relationship of adverse events with age, gender, fluoroscopy time, vital signs, and trainee presence was analyzed with the Fisher exact or the Wilcoxon rank sum 2-sided tests. MAIN OUTCOME MEASURES: The frequency of immediate (during or immediately after the procedure) or delayed (within 24-72 hours after the procedure) adverse events.
RESULTS: A total of 162 patients (133 women) underwent 191 procedures. The range of subject age was from 20 to 90 years (15.8 years, standard deviation [SD]). The range (SD) of the preprocedure 11-point Likert Pain Scale was from 1.0 to 10.0 (2.0) and for the postprocedure 11-point Likert Pain Scale was from 0.0 to 9.0 (2.5). Trainees were involved in 57% of the procedures. Reported immediate adverse events were vasovagal reaction (2.1% [n = 4]) and steroid-clogged needle (0.5% [n = 1]). Follow-up data were available for 132 of 191 procedures (69%). There were 32 adverse events reported at a mean follow-up interval of 2 days, of which, the most frequent adverse events were injection-site soreness (12.9% [n = 17]), pain exacerbation (5.3% [n = 7]), and facial flushing and/or sweating (2.3% [n = 3]). Delayed adverse events decreased with older age (P = .0029). The patients who underwent bilateral procedures experienced more delayed adverse events than the patients who underwent unilateral procedures (P = .024).
CONCLUSIONS: Fluoroscopically guided IASIJ injection is associated with minimal adverse effects. The most common immediate adverse event was vasovagal reaction, and the most common delayed adverse event was injection-site soreness. Younger age is significantly related to reported delayed adverse events.
Copyright © 2012 American Academy of Physical Medicine and Rehabilitation. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22543036     DOI: 10.1016/j.pmrj.2012.02.001

Source DB:  PubMed          Journal:  PM R        ISSN: 1934-1482            Impact factor:   2.298


  4 in total

1.  Vasovagal rates in flouroscopically guided interventional procedures: a study of over 8,000 injections.

Authors:  David J Kennedy; Byron Schneider; Ellen Casey; Joshua Rittenberg; Bryan Conrad; Matthew Smuck; Christopher T Plastaras
Journal:  Pain Med       Date:  2013-10-04       Impact factor: 3.750

2.  Pelvic belt effects on pelvic morphometry, muscle activity and body balance in patients with sacroiliac joint dysfunction.

Authors:  Odette Soisson; Juliane Lube; Andresa Germano; Karl-Heinz Hammer; Christoph Josten; Freddy Sichting; Dirk Winkler; Thomas L Milani; Niels Hammer
Journal:  PLoS One       Date:  2015-03-17       Impact factor: 3.240

3.  Pelvic Belt Effects on Health Outcomes and Functional Parameters of Patients with Sacroiliac Joint Pain.

Authors:  Niels Hammer; Robert Möbius; Stefan Schleifenbaum; Karl-Heinz Hammer; Stefan Klima; Justin S Lange; Odette Soisson; Dirk Winkler; Thomas L Milani
Journal:  PLoS One       Date:  2015-08-25       Impact factor: 3.240

4.  The Role of Sacroiliac Joint Steroid Injections in the Treatment of Axial Spondyloarthritis.

Authors:  Serdar Kokar; Önder Kayhan; Savaş Şencan; Osman Hakan Gündüz
Journal:  Arch Rheumatol       Date:  2021-01-14       Impact factor: 1.472

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.